Definium tees up regulatory submission for psychedelic on Phase III hat trick

NDA FilingDT120Positive

AI Analysis

Summary

Definium Therapeutics plans to submit an NDA for its LSD-based psychedelic DT120 in generalised anxiety disorder during H1 2027, following successful Phase 3 trials.

Clinical Trial Data

Phase

Phase 3

Importance:6/10

Sentiment:

0.50

psychedelicNDA submissionPhase 3anxiety disorderregulatory pathway

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 15, 2026 10:03 AM

Read Original